Number of isolates susceptible, intermediate, and resistant to aminoglycosides, determined using CLSI, EUCAST, and FDA breakpoints, including all isolates studied. S, susceptible; I, CLSI intermediate and EUCAST susceptible increased exposure categories; R, resistant; PLZ, plazomicin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin.